Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Stanford University
Intima Bioscience, Inc.
University of Pittsburgh
Immatics US, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Northwestern University
Cancer Research UK